Download PDF
Onkologische Welt 2024; 15(05): 267
DOI: 10.1055/a-2334-3872
Editorial

Goldene Zeiten

Alexander Kretzschmar∗
› Further Information
Also available at
    Permissions and Reprints
Zoom Image
Dr. Alexander Kretzschmar


Publication History

Article published online:
03 September 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Blank CU. et al Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. J Clin Oncol 2024; 42 (Suppl. 17) LBA2
    CrossrefSearch in Google Scholar
  • 2 Patel SP. et al Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.. N Engl J Med 2023; 388: 813-823
    CrossrefPubMedSearch in Google Scholar
  • 3 Ramalingam SS. et al Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study.. J Clin Oncol 2024; 42 (Suppl. 17) LBA4
    CrossrefSearch in Google Scholar
  • 4 Solomon BJ. et al Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.. J Clin Oncol 2024; 42 (Suppl. 17) LBA8503
    CrossrefSearch in Google Scholar
  • 5 Spigel DR. et al ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).. J Clin Oncol 2024; 42 (Suppl. 17) LBA5
    CrossrefSearch in Google Scholar